Skip to content

Moxidectin

FDA-approved product (tablet, oral), marketed as Moxidectin.

Registered studies
25
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Moxidectin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Helminthiasis
  • Onchocerciasis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antinematodals
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P02CX03

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae41.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

25registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Moxidectin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis

    NCT04056325 · start 2019-11-27

    Registered record
    Registry ID
    NCT04056325
    Conditions
    Strongyloides Stercoralis Infection
    Interventions
    Moxidectin; Ivermectin; Placebo oral tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2019-11-27
    Completion
    2021-04-30
    Enrolment
    617

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStrongyloides Stercoralis Infection
    InterventionMoxidectin; Ivermectin; Placebo oral tablet
    PhasePhase 2 / Phase 3
    Registry statusCompleted
  • Estimating the Malaria Prevention Impact of New Nets: Observational Analyses to Evaluate the Evidence Generated During Piloted New Net Distributions in Burkina Faso

    NCT04157894 · start 2019-07-07

    Registered record
    Registry ID
    NCT04157894
    Conditions
    Malaria
    Interventions
    Standard long-lasting insecticidal net; Chlorfenapyr insecticide treated net; Piperonyl butoxide long-lasting insecticidal net
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-07-07
    Completion
    2022-07-06
    Enrolment
    5,606

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionStandard long-lasting insecticidal net; Chlorfenapyr insecticide treated net; Piperonyl butoxide long-lasting insecticidal net
    PhaseNot recorded
    Registry statusCompleted
  • Efficacy and Safety of Ascending Dosages of Moxidectin and Moxidectin-albendazole Against Trichuris Trichiura

    NCT03501251 · start 2018-07-03

    Registered record
    Registry ID
    NCT03501251
    Conditions
    Trichuris Trichiura; Infection
    Interventions
    Moxidectin 8mg; Moxidectin 8 mg + albendazole 400 mg; Moxidectin 16 mg; Moxidectin 16 mg + albendazole 400 mg; Moxidectin 24 mg; Moxidectin 24 mg + albendazole 400 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-07-03
    Completion
    2018-08-11
    Enrolment
    286

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTrichuris Trichiura; Infection
    InterventionMoxidectin 8mg; Moxidectin 8 mg + albendazole 400 mg; Moxidectin 16 mg; Moxidectin 16 mg + albendazole 400 mg +3 more
    PhasePhase 2
    Registry statusCompleted
  • Effect of a Single Oral Dose of Moxidectin on the Cardiac QT Interval of Healthy Volunteers

    NCT03012828 · start 2017-01

    Registered record
    Registry ID
    NCT03012828
    Conditions
    QT Effects in Healthy Volunteers
    Interventions
    Moxidectin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-01
    Completion
    2017-05
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionQT Effects in Healthy Volunteers
    InterventionMoxidectin; Placebo
    PhasePhase 1
    Registry statusCompleted
  • Pediatric Pharmacokinetics And Safety Study Of Moxidectin

    NCT01035619 · start 2011-04

    Registered record
    Registry ID
    NCT01035619
    Conditions
    Onchocerciasis
    Interventions
    moxidectin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2011-04
    Completion
    2011-04
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOnchocerciasis
    Interventionmoxidectin
    PhasePhase 2
    Registry statusWithdrawn
  • Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection

    NCT00790998 · start 2009-04

    Registered record
    Registry ID
    NCT00790998
    Conditions
    Onchocerciasis
    Interventions
    Moxidectin; Ivermectin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-04
    Completion
    2012-05
    Enrolment
    1,497

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOnchocerciasis
    InterventionMoxidectin; Ivermectin
    PhasePhase 3
    Registry statusCompleted
  • Study Evaluating The Co-Administration Of Moxidectin And Midazolam In Healthy Subjects

    NCT00856362 · start 2009-04

    Registered record
    Registry ID
    NCT00856362
    Conditions
    Healthy
    Interventions
    Moxidectin; Midazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-04
    Completion
    2009-09
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMoxidectin; Midazolam
    PhasePhase 1
    Registry statusCompleted
  • Study Evaluating The Effect Of High-Fat Meal On Bioavailability And Pharmacokinetics Of Single Dose Of Moxidectin

    NCT00736697 · start 2008-11

    Registered record
    Registry ID
    NCT00736697
    Conditions
    Infection
    Interventions
    moxidectin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-11
    Completion
    2009-05
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection
    Interventionmoxidectin
    PhasePhase 1
    Registry statusCompleted
  • Study Evaluating The Excretion Of Moxidectin Into The Breast Milk Of Lactating, Non-Breastfeeding Women

    NCT00751764 · start 2008-11

    Registered record
    Registry ID
    NCT00751764
    Conditions
    Infection
    Interventions
    Moxidectin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-11
    Completion
    2009-09
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection
    InterventionMoxidectin
    PhasePhase 1
    Registry statusCompleted
  • Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection

    NCT00300768 · start 2006-09-06

    Registered record
    Registry ID
    NCT00300768
    Conditions
    Onchocerciasis
    Interventions
    2 mg moxidectin; ivermectin 150 mcg/kg; 4 mg moxidectin; 8 mg moxidectin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-09-06
    Completion
    2009-11-29
    Enrolment
    172

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOnchocerciasis
    Intervention2 mg moxidectin; ivermectin 150 mcg/kg; 4 mg moxidectin; 8 mg moxidectin
    PhasePhase 2
    Registry statusCompleted